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Objective: The addition of bevacizumab to ﬂuoropyrimidine-based combination chemother-
apy as ﬁrst-line therapy for metastatic colorectal cancer results in clinically signiﬁcant
improvements in patient outcome. However, clinical trials have been conducted primarily in
Caucasian patients with only a small proportion of Asian patients. This Phase I/II study was
designed to evaluate the efﬁcacy and safety of XELOX (capecitabine plus oxaliplatin) plus
bevacizumab in Japanese patients with metastatic colorectal cancer.
Methods: Patients with previously untreated, measurable metastatic colorectal cancer
received bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m
2 on day 1, plus capecitabine
1000 mg/m
2 twice daily on days 1–14, every 3 weeks. A three-step design evaluated in: step
1, initial safety of XELOX in six patients; step 2, initial safety of XELOX plus bevacizumab in
six patients; and step 3, efﬁcacy and safety in a further 48 patients. The primary study end-
points were safety and response rate.
Results: No dose-limiting toxicity occurred during Steps 1 and 2. Fifty-eight patients were
enrolled in Steps 2 and 3 and received XELOX plus bevacizumab. In the 57 patients
assessed for response, the overall response rate was 72% (95% conﬁdence interval, 58.5–
83.0). Median progression-free survival was 11.0 months (95% conﬁdence interval, 9.6–
12.5) and median overall survival was 27.4 months (95% conﬁdence interval, 22.0–not calcu-
lated). Eight patients (14%) underwent surgery with curative intent. The most common grade
3/4 adverse events were neurosensory toxicity (17%) and neutropenia (16%).
Conclusions: XELOX plus bevacizumab is effective and has a manageable tolerability
proﬁle when given to Japanese patients with metastatic colorectal cancer.
Key words: xelox – bevacizumab – colorectal cancer – Japanese
INTRODUCTION
Colorectal cancer is the third leading cause of cancer deaths
worldwide. The number of patients affected by this disease
continues to increase steadily (1–3)a n d42 000 deaths
occur annually in Japan (3).
FOLFOX4, a bi-weekly schedule of intravenous bolus and
infusional 5-ﬂuorouracil/folinic acid plus oxaliplatin
(Elplat
w) is a widely used regimen for the ﬁrst-line treatment
of metastatic colorectal cancer (MCRC) (4,5). However, oral
ﬂuoropyrimidines can replace the intravenous
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Capecitabine (Xeloda
w) is an oral ﬂuoropyrimidine with
similar efﬁcacy to bolus 5-ﬂuorouracil/folinic acid when
given as ﬁrst-line treatment for MCRC (6–8) or as adjuvant
therapy for stage III colon cancer (9). It has also been suc-
cessfully combined with oxaliplatin as the capecitabine plus
oxaliplatin (XELOX) regimen, which consists of a 21-day
intermittent schedule of capecitabine combined with a
3-weekly dose of oxaliplatin (10,11). A pivotal phase III
study (NO16966) recently demonstrated that XELOX was
non-inferior in terms of efﬁcacy to FOLFOX4 as the ﬁrst-
line treatment for patients with MCRC (12). The same study
further showed that adding bevacizumab (Avastin
w)t o
oxaliplatin-based chemotherapy signiﬁcantly improved
progression-free survival (PFS) by 20% in the ﬁrst-line treat-
ment of MCRC (13). However, most of the clinical develop-
ment of these regimens has been performed in Europe and
the USA, although the NO16966 study included a small
number of centers in Central and Eastern Asia (12,13). It has
not been clariﬁed if XELOX with the dose and schedule
applied mainly to Caucasian patients shows a similar efﬁ-
cacy and toxicity proﬁle in Japanese patients. To address this
issue, we conducted a Phase I/II study to evaluate the safety
and efﬁcacy of XELOX plus bevacizumab in Japanese
patients with MCRC.
PATIENTS AND METHODS
STUDY DESIGN
A prospective, multicenter, open-label study with a three-
step design was conducted to evaluate the efﬁcacy and safety
of the commonly used dose of XELOX plus bevacizumab in
Japanese patients with MCRC. The purpose of step 1 was to
evaluate the initial safety of XELOX in six patients; step 2
was to evaluate the initial safety of XELOX plus bevacizu-
mab in six patients; and step 3 was to evaluate the efﬁcacy
and safety of XELOX plus bevacizumab in 48 patients plus
the six patients from step 2. The criterion for proceeding to
the next phase was the occurrence of dose-limiting toxicity
(DLT) in less than or equal to two of six patients. An inde-
pendent review committee (IRC) was scheduled to evaluate
safety immediately after the ﬁrst cycle in steps 1 and 2. The
previous phase I trial determined the recommended dose of
the XELOX regimen (14) and DLT was deﬁned as grade 4
neutropenia for 5 days or more, or febrile neutropenia, or
grade  3 neutropenia associated with grade 3/4 compli-
cations (e.g. stomatitis, diarrhea); or grade  3 gastrointesti-
nal toxicities, grade 3 hand-foot syndrome (HFS), grade  3
peripheral neuropathy, or any grade 4 hematological toxicity
or any other clinically signiﬁcant grade  3n o n -
hematological toxicity which did not recover within 2 days
with appropriate therapy.
The study was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice. Written
informed consent was obtained from all patients participating
in this study. The protocol was approved by the independent
ethics committee or institutional review board at each site.
PATIENTS
At study enrollment, patients were required to fulﬁll all of
the following criteria: age  20 and  74 years, Eastern
Cooperative Oncology Group (EGOG) performance status of
0 or 1, life expectancy  3 months, histologically proven
adenocarcinoma of the colon or rectum that was considered
to be unrespectable with at least one measurable metastasis
(RECIST guidelines) (15), no prior systemic chermotherapy
for MCRC, no progression within 6 months of adjuvant
therapy completion (if received), neutrophil count  1500/
mm
3, platelet count  100 000/mm
3, hemoglobin level
 9.0 g/dl, total bilirubin  1.5 times the institutional upper
limit of normal (ULN), aspartate aminotransferase (AST),
alanine aminotransferase and alkaline phosphatase  2.5
times ULN, creatinine  1.5 times ULN and creatinine clear-
ance  50 ml/min. Some of the exclusion criteria were as
follows: brain tumors or brain metastases, clinically detect-
able ascites; major surgery, open biopsy or signiﬁcant trau-
matic injury within 4 weeks before enrollment, ﬁne needle
aspiration biopsy or central venous line placement within 1
week before enrollment, bleeding diathesis or coagulopathy,
international normalized ratio  1.5 within 1 week before
enrollment, non-healing bone fracture, urinary protein  1þ
within 1 week before enrollment, uncontrolled hypertension
or peptic ulcer, clinically signiﬁcant cardiovascular disease,
chronic, daily treatment with high-dose aspirin ( 325 mg/
day) or non-steroidal anti-inﬂammatory medications, or per-
ipheral neuropathy of at least grade 1. The inclusion and
exclusion criteria were almost identical to those used in the
NO16966 study (12,13).
TREATMENT
Oxaliplatin was supplied by Yakult Honsha Co., Ltd (Tokyo,
Japan) and capecitabine and bevacizumab were supplied by
Chugai Pharmaceutical Co., Ltd (Tokyo, Japan). XELOX
consisted of a 2-h intravenous infusion of oxaliplatin
130 mg/m
2 on day 1 plus oral capecitabine 1000 mg/m
2
twice daily for 2 weeks of a 3-week cycle. The ﬁrst dose of
capecitabine was given in the evening of day 1 and the last
dose in the morning of day 15. Bevacizumab at a dose of
7.5 mg/kg was administered as a 30- to 90-min intravenous
infusion before oxaliplatin on day 1 of the 3-week cycle.
Treatment was continued until disease progression, intoler-
able adverse events or withdrawal of consent.
Treatment was to be interrupted if grade 2–4 toxicities
occurred. No dose modiﬁcation of bevacizumab was per-
formed. The dose of capecitabine was to be adjusted for
grade 3 or 4 thrombocytopenia or neutropenia, febrile neu-
tropenia or non-hematological toxicities of grade 2 or
higher, according to a standard scheme described in detail
by Blum et al. (16). The dose of oxaliplatin was to be
914 XELOX plus bevacizumab for MCRC in Japanreduced to 100 or 85 mg/m
2 if patients experienced grade 3
or 4 thrombocytopenia or neutropenia, febrile neutropenia,
or grade 3 non-hematological toxicity, and for grade 3 neu-
rosensory toxicity lasting more than 7 days, or grade 2 neu-
rosensory toxicity persisting between cycles. For grade 3
neurosensory toxicity persisting between cycles, oxaliplatin
was to be discontinued. This treatment plan was almost iden-
tical to that of the NO16966 study (12,13).
If oxaliplatin and/or bevacizumab were discontinued, treat-
ment with the remaining components could be continued,
such as capecitabine with or without bevacizumab after dis-
continuation of oxaliplatin, and XELOX or capecitabine after
discontinuation of bevacizumab. Continuation of oxaliplatin
or bevacizumab without capecitabine was not permitted.
EFFICACY AND SAFETY EVALUATION
Tumor assessments with computed tomography scan were
performed within 2 weeks before registration to this study
and repeated every 6 weeks. Response rate was evaluated by
the investigators according to RECIST version 1.0 (15).
Tumor responses were conﬁrmed by the IRC.
PFS was deﬁned as the duration from the date of the ﬁrst
dose of the study drug to the date of ﬁrst conﬁrmation of
disease progression as determined by the IRC, or death from
any cause, and censored at the last tumor assessment if a
patient withdrew before progression. Overall survival (OS)
was deﬁned as the duration from the ﬁrst dose of study drug
to death. Time to response was deﬁned as the time interval
from the ﬁrst dose of study drug to the ﬁrst detection of
 30% decrease of tumor size assessed by the IRC for
patients with a conﬁrmed overall response of PR or CR.
Response duration was deﬁned as the time interval from the
ﬁrst detection of  30% decrease of tumor size to disease
p r o g r e s s i o na s s e s s e db yt h eI R Ca n dc e n s o r e da tt h el a s t
tumor assessment if a patient withdrew before progression.
Safety was assessed weekly for the ﬁrst eight cycles of the
treatment. Adverse events were evaluated according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0 (17). All adverse events were
evaluated until 28 days after the last dose of study drug.
STATISTICAL ANALYSIS
The primary study endpoints were safety and overall
response rate (ORR) as assessed by the IRC. Secondary end-
points were PFS, OS, time to response and response
duration.
Forty-eight patients were required to test the null hypoth-
esis (P ¼ p0 or lower) versus the alternative hypothesis (P ¼
pA or higher) with a one-sided a-level of 2.5% and a power
of 80% when the critical ORR (p0) was 35% and the
expected ORR (pA) was 55%. The total number of patients
recruited to receive XELOX plus bevacizumab was estimated
to be 54 (6 for Step 2 and 48 for Step 3) to allow for patients
who might be ineligible for efﬁcacy evaluation.
ORRs were presented with 95% conﬁdence interval (CI).
The probabilities of time-to-event parameters were estimated
using the Kaplan–Meier method with 95% CI.
RESULTS
PATIENT CHARACTERISTICS
A total of 64 patients were enrolled between February 2006
and November 2006 from 11 centers in Japan. Six patients
were enrolled in step 1 and received XELOX and 58 patients
w e r ee n r o l l e di ns t e p s2a n d3a n dr e c e i v e dX E L O Xp l u s
bevacizumab. All patients (n ¼ 64) were included in the
safety analysis. One patient was excluded from the efﬁcacy
analysis because he received bevacizumab as part of a differ-
ent clinical trial. Therefore, six patients were included in the
efﬁcacy evaluation of XELOX and 57 patients were included
in the efﬁcacy evaluation of XELOX plus bevacizumab.
The baseline demographic characteristics of the enrolled
study patient population are shown in Table 1. The median
age of the patients treated with XELOX was 58.5 years
(range, 40–68 years) and with XELOX plus bevacizumab
was 57.0 years (range, 33–74 years). ECOG performance
status with XELOX was 0 in all 6 patients, and with
XELOX plus bevacizumab was 0 in 50 patients and 1 in 8
patients.
TREATMENT DURATION
In the six patients participating in step 1, the median dur-
ation of treatment was 6.5 months (range, 0.5–14 months)
with a median of 8.5 treatment cycles (range, 1–17 cycles).
XELOX combination therapy was administered for a median
of 7.0 cycles (range, 1–17 cycles). One patient subsequently
went on to receive a further 6 cycles of capecitabine mono-
therapy for a total of 13 cycles.
In steps 2 and 3, the median duration of treatment was 7.6
months (range, 0.1–34.8 months) with a median of 10.5
treatment cycles (range, 1–47 cycles). XELOX plus bevaci-
zumab combination therapy was administered for a median
of 9.0 cycles (range, 1–27 cycles). After discontinuation of
oxaliplatin, 17 patients (29%) continued with capecitabine
and bevacizumab combination therapy and received a
median of 5.0 cycles (range, 1–34 cycles). Four patients
(7%) received XELOX therapy for a median of 2.0 cycles
(range, 1–5 cycles) during permanent or temporary discon-
tinuation of bevacizumab.
The median relative dose intensity (ratio of dose received
to dose planned) was 0.74 (range: 0.41–1.00) for capecita-
bine, 0.86 (range: 0.55–1.00) for oxaliplatin and 0.91
(range: 0.58–1.01) for bevacizumab.
EFFICACY
At the ﬁnal data cut-off date (30 June 2009), the median dur-
ation of follow-up was 32.0 months. Thirty-three patients
Jpn J Clin Oncol 2010;40(10) 915had died of disease progression and two patients were still
receiving study medication. Tumor responses (ORR, time to
response, response duration and PFS) are based on the
median duration of follow-up of 15.2 months.
The analysis of efﬁcacy is shown in Table 2.T h eO R R
(complete plus partial response) with XELOX was 67% (4/6)
(95% CI: 22.3–95.7%), and with XELOX plus bevacizumab
was 72% (41/57) (95% CI: 58.5–83.0%). The median PFS
with XELOX plus bevacizumab was 11.0 months (95% CI:
9.6–12.5 months) (Fig. 1) and the median OS was 27.4
months (95% CI: 22.0 months–not calculated) (Fig. 2).
Eight patients (14%) treated with XELOX plus bevacizu-
mab underwent surgery with curative intent: none experi-
enced a serious adverse event as a result of surgery and four
patients (7%) had no residual disease. The sites of resection
being curative by surgery were liver (n ¼ 7), lymph node
(n ¼ 1), cholesyst (n ¼ 2) and colon primary tumor (n ¼ 2).
SAFETY
N oD L To c c u r r e dd u r i n ge i t h e rs t e p1o rs t e p2 .A l ls i x
patients treated with XELOX and 31 (53%) patients treated
with XELOX plus bevacizumab discontinued study treatment
because of disease progression. Ten (17%) patients withdrew
from XELOX plus bevacizumab because of adverse events,
which comprised dehydration and anorexia; gastric varices
haemorrhage; enteritis infectious; anorexia, herpes zoster and
nausea; neutropenia; AST increased and alanine aminotrans-
ferase increased; infected epidermal cyst; peripheral sensory
neuropathy; epididymitis; HFS (one patient, respectively). No
patient died within 28 days after study medication.
All patients (n ¼ 64) experienced at least one adverse
event during the study, most of which were mild to moderate
in severity (Table 3). The most common adverse events with
XELOX plus bevacizumab were neurosensory toxicity
(93%), anorexia (90%), fatigue (83%) and HFS (78%). The
most common grade 3/4 adverse events were neurosensory
toxicity (17%) and neutropenia (16%).
For patients receiving XELOX plus bevacizumab, dose
reductions were required for capecitabine in 32 patients
(55.2%); the major reasons were HFS (n ¼ 7), neutropenia
(n ¼ 6) and diarrhea (n ¼ 6). Capecitabine doses were reduced
to 75% of starting dose in 18 patients and to 50% in 14
patients. Dose reductions were required for oxaliplatin in 30
patients (51.7%) due to neurosensory toxicity (n ¼ 15), neutro-
penia (n ¼ 7) and other toxicities, and in most of
Table 2. Analysis of efﬁcacy
Endpoint XELOX
(n ¼ 6)
XELOX plus
bevacizumab (n ¼ 57)
Median progression-free
survival, months
8.3 11.0
95% conﬁdence interval 5.8–13.8 9.6–12.5
Median overall survival,
months
– 27.4
95% conﬁdence interval – 22.0-NC
Response rate, % 67 72
95% conﬁdence interval 22.3–95.7 58.5–83.0
Complete response 0 2
Partial response 4 39
Stable disease 1 9
Progressive disease 0 1
Not evaluable 1 6
Median time to response,
months
2.6 2.7
95% conﬁdence interval 1.2–NC 1.5–2.8
Median response duration,
months
6.4 9.7
95% conﬁdence interval 2.8–11.3 6.7–9.9
NC, not calculated.
Table 1. Baseline demographic characteristics
Characteristic XELOX (n ¼ 6) XELOX plus
bevacizumab (n ¼ 58)
No. of patients % No. of patients %
Sex
Male 5 83 40 69
Female 1 17 18 31
Age
Median 58.5 57.0
Range 40–68 33–74
ECOG performance status
0 6 100 50 86
10 0 8 1 4
Primary tumor site
Colon 4 67 31 53
Rectum 2 33 27 47
Metastatic site
Liver 5 83 45 78
Lung 2 33 28 48
Lymph node 0 0 27 47
Other 3 50 5 9
No. of organs involved
1 2 33 25 43
2 4 67 21 36
30 0 1 0 1 7
.30 0 2 3
Adjuvant therapy
Yes 1 17 8 14
No 5 83 50 86
ECOG, Eastern Cooperative Oncology Group.
916 XELOX plus bevacizumab for MCRC in Japanthese patients (n ¼ 27) the oxaliplatin dose was reduced to
100 mg/m
2.
DISCUSSION
In this prospective trial for Japanese patients with MCRC,
XELOX plus bevacizumab achieved a high response rate of
72%, and eight patients (14%) proceeded to surgery with
curative intent. The median PFS and the median OS for
XELOX plus bevacizumab were 11.0 and 27.4 months,
respectively.
Previous randomized or observational trials which
included the XELOX plus bevacizumab regimen as ﬁrst-line
therapy have been conducted mainly in North America and
Europe (13,18–22). The NO16966 study showed a longer
PFS and OS in the XELOX plus bevacizumab arm compared
with the XELOX plus placebo arm in a subgroup analysis,
which reported a median PFS of 9.3 versus 7.4 months,
HR ¼ 0.77 (95% CI: 0.63–0.94, P ¼ 0.0026) and a median
OS of 21.6 versus 19.0 months (HR was not shown) (23,24).
Furthermore, another phase III trial (CAIRO2) reported a
response rate of 50.0%, a median PFS of 10.7 months and a
median OS of 20.3 months in the XELOX plus bevacizumab
arm (18). The patient baseline demographic characteristics
of the enrolled study patient population were similar to those
of previous clinical trials in Western patients, except that the
proportion of rectal cancer whose prognosis is worse than
that of colon cancer was higher in this study (47% versus
23–35%) (4,6–8,11,12). Thus, the efﬁcacy data from our
study compares favorably with that reported in other recently
conducted studies in predominantly Western patients,
although in comparing the efﬁcacy data from 57 patients of
this single arm study to those of randomized phase III trials
caution should be exercised.
The administration schedule and doses selected for our
study were identical to those used in the NO16966 study
(12,13). The median relative dose intensity was similar with
that in the XELOX plus bevacizumab arm of the NO16966
Figure 1. Progression-free survival (XELOX plus bevacizumab).
Figure 2. Overall survival (XELOX plus bevacizumab). NC, not calculated.
Jpn J Clin Oncol 2010;40(10) 917study (0.74 versus 0.73 for capecitabine, 0.86 versus 0.81 for
oxaliplatin and both 0.91 for bevacizumab). The relative dose
intensity was reported in another phase II trial (TREE-2) as
well, a median of 0.76 for capecitabine, 0.91 for oxaliplatin
and 0.96 for bevacizumab in the XELOX plus bevacizumab
arm, whereas the starting dose of capecitabine was reduced to
850 mg/m
2 twice daily and the median duration of the therapy
was 19 weeks in that study (14). The safety proﬁle observed
in our study was similar to that observed in previous clinical
trials with Western patients, including the NO16966 study
(12,13,18–22). It is notable that the incidence of grade 3/4
diarrhea was only 3%, which is considerably lower than that
reported with XELOX plus bevacizumab in the previous
phase II and III studies (19–21%) (12,18,19,22). A lower
incidence of diarrhea has been reported in other studies of
Japanese or Asian patients treated with ﬂuoropyrimidine-based
chemotherapy (25–27). In addition, clinical trials including
other oral ﬂuoropyrimidines, such as UFT, have reported
lower incidence of grade 3/4 diarrhea in Japanese patients
than in Western patients (9.1 versus 22.2%) (28). A reason for
this regional variation remains unclear, but it is speculated
that differences in dietary folate intake may be a potential
explanation (29). Regarding to HFS, although the overall inci-
dence of HFS in our study (78%) was higher than that in the
XELOX plus bevacizumab arm of the NO16966 study (39%),
the incidence of grade 3 HFS appeared signiﬁcantly lower (2
versus 12%). The incidence of dose modiﬁcation (including
treatment interruption and delay) due to HFS was similar
among the studies (data not shown), as well as the dose inten-
sity of capecitabine as described above. Therefore, the differ-
ence in incidences of grade 3 HFS, unfortunately, is not well
explained at this time. However, a number of factors may
explain this difference. The dose modiﬁcation of capecitabine
due to adverse events other than HFS (e.g. neutropenia,
increase of AST, fatigue, anorexia), which occurred at higher
incidences in our study compared with the NO16966 study,
might be one such factor (data not shown). Difference in fre-
quency of visits could also be factor. Patients received
medical examination once every week during ﬁrst eight cycles
in this study, resulting in the treatment interruption in the
middle of ﬁrst 2 weeks of a cycle in four patients among
eleven patients who developed grade 2 or grade 3 HFS.
Another potential reason might be differences in prophylactic
administration (e.g. a moisturizer, steroid ointment, urea oint-
ment etc.). In terms of hematologic toxicities, grade 3/4 neu-
tropenia occurred at 16% in patients receiving XELOX plus
bevacizumab in our study which was higher than in the
XELOX/XELOX þ placebo arm of the NO16966 study (6%)
(12), whereas no febrile neutropenia was observed in any
patient in our study. The difference in the incidence of grade
3/4 neutropenia may in part be derived from an increased fre-
quency of hematological examination, which was performed
once every week in this study in contrast to once every 3
weeks at day 1 in the pivotal phase III study. Known
bevacizumab-speciﬁc events (i.e. coagulopathy, hypertension,
bleeding) were generally mild to moderate in severity in our
study, and grade 3/4 events occurred at similar or lower inci-
dence to that reported in Western patients (13). It is concluded
that XELOX plus bevacizumab is well tolerated in Japanese
patients with MCRC.
Only one patient (2%) treated with XELOX plus bevaci-
zumab experienced grade 3 HFS, compared with an inci-
dence of 13% in a previous phase II study of capecitabine
monotherapy (1250 mg/m
2 twice daily) in Japanese patients
with MCRC (25). In addition, dose reduction of capecitabine
due to HFS was required for less patients in our study (12.1
versus 31.7%). This may be attributable to the 20% reduced
dose of capecitabine used in the XELOX regimen compared
with capecitabine monotherapy.
In the present trial, six patients received only XELOX.
The ORR was 67%, grade 3 adverse events developed in
three patients (one event each, respectively) and no signiﬁ-
cant safety ﬁnding was observed. XELOX without bevacizu-
mab is a widely used regimen in a ﬁrst-line setting for
MCRC patients (NCCN guideline) (30). The NO16966 study
demonstrated an encouraging efﬁcacy as described above,
and another phase III trial showed an ORR of 42%; PFS of
9.3 months; and median OS of 19.9 months in the XELOX
arm, with a good safety proﬁle (31). Thus, XELOX seems to
be acceptable as an option for a standard regimen for MCRC
in Japan, although the data provided in our study is limited
to a small population.
Table 3. Incidence of common adverse events
Adverse event XELOX (n ¼ 6) XELOX plus
bevacizumab (n ¼ 58)
Grade
1–4
Grade
3–4
Grade
1–4
Grade
3–4
No. % No. % No. % No. %
Neurosensory toxicity 6 100 1 17 54 93 10 17
Anorexia 5 83 0 0 52 90 2 3
Fatigue 4 67 0 0 48 83 3 5
Hand-foot syndrome 4 67 1 17 45 78 1 2
Nausea 6 100 0 0 43 74 0 0
Pigmentary disturbance 2 33 0 0 36 62 0 0
Stomatitis 2 33 0 0 33 57 1 2
Diarrhea 4 67 0 0 32 55 2 3
Neutropenia 3 50 0 0 30 52 9 16
Vomiting 1 17 0 0 27 47 1 2
Nose bleed 1 17 0 0 23 40 0 0
Proteinuria 0 0 0 0 19 33 3 5
Hypertension 0 0 0 0 19 33 3 5
Thrombocytopenia 2 33 1 17 13 22 4 7
Pulmonary thrombosis 0 0 0 0 1 2 1 2
Jugular vein thrombosis 0 0 0 0 1 2 0 0
918 XELOX plus bevacizumab for MCRC in JapanIn conclusion, in this study, XELOX plus bevacizumab
was effective with manageable tolerability proﬁle for
Japanese patients with MCRC. The efﬁcacy and safety
proﬁle of XELOX plus bevacizumab in this study was con-
sistent with that observed in Western patients, whereas
showing a notably lower incidence of diarrhea. Moreover,
the XELOX regimen requires only one visit per 3-week
cycle for a 2- or 3-h infusion, which may provide a marked
advantage over the FOLFOX regimen in terms of the con-
venience for both patients and clinical staff. Therefore,
XELOX plus bevacizumab may be considered as a possible
standard treatment for Japanese patients with MCRC.
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Appendix
The following investigators cared for the patients in this
study: Kuniaki Shirao (Oita University, Faculty of Medicine,
Yufu, Oita) and Takashi Sekikawa (Toyosu Hospital, Showa
University School of Medicine, Tokyo).
920 XELOX plus bevacizumab for MCRC in Japan